Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0SACUI
ADC Name	BB-1705
Synonyms	BB1705 BB 1705 Click to Show/Hide
Organization	Baili Sikang Biomedicine (Hangzhou) Co., Ltd.
Drug Status	Phase 1/2
Indication	In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 2
Drug-to-Antibody Ratio	2
Structure
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	Eribulin		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05217693	Phase 1/2	A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05217693	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors.

References

Ref 1	A Phase I/II First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors, NCT05217693